District court

SSR MINING SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against SSR Mining Inc. - SSRM

Retrieved on: 
Wednesday, April 24, 2024
KSF, District court, Court, SSRM, SSR

NEW ORLEANS, April 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against SSR Mining Inc. (NasdaqGS: SSRM), if they purchased the Company’s securities between February 23, 2022 and February 27, 2024, inclusive (the “Class Period”).

Key Points: 
  • NEW ORLEANS, April 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against SSR Mining Inc. (NasdaqGS: SSRM), if they purchased the Company’s securities between February 23, 2022 and February 27, 2024, inclusive (the “Class Period”).
  • This action is pending in the United States District Court for the District of Colorado.
  • If you purchased securities of SSR and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ssrm/ to learn more.
  • If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 17, 2024.

IROBOT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against iRobot Corporation - IRBT

Retrieved on: 
Wednesday, April 24, 2024
KSF, IRBT, District court, Court, IRobot

NEW ORLEANS, April 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 7, 2024 to file lead plaintiff applications in a securities class action lawsuit against iRobot Corporation (NasdaqGS: IRBT), if they purchased the Company’s securities between August 5, 2022 and January 26, 2024, inclusive (the “Class Period”).

Key Points: 
  • NEW ORLEANS, April 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 7, 2024 to file lead plaintiff applications in a securities class action lawsuit against iRobot Corporation (NasdaqGS: IRBT), if they purchased the Company’s securities between August 5, 2022 and January 26, 2024, inclusive (the “Class Period”).
  • This action is pending in the United States District Court for the District of New Jersey.
  • If you purchased securities of iRobot and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-irbt/ to learn more.
  • If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 7, 2024.

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Retrieved on: 
Wednesday, April 24, 2024
Core, FDA, Ipsen, Food, Pancreatic cancer, Oxaliplatin, RNA, Webcast, Patent, ADC, District court, Fluorouracil, Patient, Paragraph, Dicarboxylic acid, DSM-IV codes, Therapy, CER1, Growth, Pharmaceutical industry

“The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines.

Key Points: 
  • “The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines.
  • Moreover, the pipeline continues to deliver, illustrated this quarter by the regulatory approval in the U.S. of Onivyde as a first-line treatment for pancreatic cancer.
  • “This year marks a pivotal period for our growth plans, with the launches of four new medicines or indications.
  • In April 2024, Ipsen announced an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate (ADC) targeting the ROR1 tumor antigen.

Fair Use Wins: Court Sides with Cribl in Splunk’s Lawsuit

Retrieved on: 
Tuesday, April 23, 2024
News, Sharp, Copyright, Digital Millennium Copyright Act, Partnership, Attention, District court, Court, DMCA, Copyright Act, SAN

The Court also ruled that Cribl’s use of Splunk’s Enterprise software for the purpose of testing and troubleshooting Cribl’s S2S integration with Splunk Enterprise is also fair use.

Key Points: 
  • The Court also ruled that Cribl’s use of Splunk’s Enterprise software for the purpose of testing and troubleshooting Cribl’s S2S integration with Splunk Enterprise is also fair use.
  • Certain other claims in Splunk’s lawsuit against Cribl were dismissed, including alleged violations of the Digital Millennium Copyright Act (DMCA), and tortious interference with prospective business relations.
  • This is great news not just for Cribl, but for the tech industry at large,” said Clint Sharp, co-founder and CEO at Cribl.
  • Critical for the industry, reverse engineering once again is affirmed by the Court as fair use under copyright law, including reverse engineering communication protocols.

Securities Class Action Filed Against Perion Network Ltd by Block & Leviton – June 17, 2024 Deadline For Lead Plaintiffs

Retrieved on: 
Wednesday, April 24, 2024
ChatGPT, News, Risk, Certification, United States district court, Growth, Complaint, District court, Microsoft, Block & Leviton

and is brought on behalf of investors that incurred damages on their purchases in Perion Network Ltd. securities between February 9, 2021 and April 5, 2024, inclusive.

Key Points: 
  • and is brought on behalf of investors that incurred damages on their purchases in Perion Network Ltd. securities between February 9, 2021 and April 5, 2024, inclusive.
  • A class has not yet been certified, and until certification occurs, you are not represented by an attorney.
  • On this news, the price of Perion Network Ltd. common stock declined by $8.61 per share, or approximately 40%, on April 8, 2024.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

GOODRX HOLDINGS, INC. (NASDAQ: GDRX) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against GoodRx Holdings, Inc.

Retrieved on: 
Tuesday, April 23, 2024
Pharmacy, LLP, News, PBM, Complaint, Action Replay, District court, Court, GoodRx, Advertising

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, inclusive (the “Class Period”).
  • If you purchased or acquired GoodRx common stock, and/or would like to discuss your legal rights and options please visit GoodRx Holdings, Inc.
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against GoodRx Holdings, Inc. (GDRX)

Retrieved on: 
Tuesday, April 23, 2024
Person, News, Risk, PBM, Complaint, District court, Defendant, GoodRx, Pharmacy, Cryptocurrency

The Complaint in the lawsuit seeks to recover damages for the Company’s investors under the federal securities laws.

Key Points: 
  • The Complaint in the lawsuit seeks to recover damages for the Company’s investors under the federal securities laws.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

RIVIAN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rivian Automotive, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 23, 2024
News, Depreciation, Complaint, P.C, Tax, District court, Court, Defendant, Telephone, Person

Investors have until June 18, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 18, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Rivian, together with its subsidiaries, designs, develops, manufactures, and sells electric vehicles and accessories.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • Among other items, Rivian announced that it expected to produce 57,000 vehicles in 2024, significantly lower than analyst expectations of 80,000 vehicles.

NASDAQ: GDRX: Kessler Topaz Meltzer & Check, LLP Files a Securities Class Action Lawsuit Against GoodRx Holdings, Inc.

Retrieved on: 
Tuesday, April 23, 2024
Lead, LLP, GO, News, Risk, PBM, Plasma protein binding, District court, HERE, Defendant, Court, GoodRx, Pharmacy, Cryptocurrency

If you suffered GoodRx losses, you may CLICK HERE or GO TO: https://www.ktmc.com/new-cases/goodrx-holdings-inc-1?utm_source=PR&utm_m...

Key Points: 
  • If you suffered GoodRx losses, you may CLICK HERE or GO TO: https://www.ktmc.com/new-cases/goodrx-holdings-inc-1?utm_source=PR&utm_m...
    You can also contact attorney Jonathan Naji, Esq.
  • of Kessler Topaz by calling (484) 270-1453 or by email at [email protected] .
  • Kessler Topaz Meltzer & Check, LLP encourages GoodRx investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

NCLA Amicus Brief Tells D.C. Circuit It Must Avoid Remanding Regulations Without Vacating Them

Retrieved on: 
Monday, April 22, 2024
NCLA, FDA, Heated tobacco product, Final, Heart, Administration, District court, Government, Human

NCLA released the following statements:

Key Points: 
  • NCLA released the following statements:
    “The ‘remand without vacatur’ doctrine licenses administrative agencies to act contrary to law with the court’s (unintentional) blessing.
  • Circuit will recognize the terrible error at the heart of this doctrine and will act accordingly.”
    “A regulation is either lawful or unlawful.
  • There is no provision for sending the rule back to the agency to simply add a missing ingredient and re-bake it.
  • Nor does the half-baked ‘remand without vacatur’ doctrine properly incentivize agencies to follow the law in the first instance.”